Cytotoxicity and genotoxicity of ({+/-})-benzo[a]pyrene-trans-7,8-dihydrodiol in CYP1A1-expressing human fibroblasts quantitatively correlate with CYP1A1 expression level

Cytochrome P450 1A1 (CYP1A1) activity is associated with increasedsusceptibility to lung cancer induced by polycyclic aromatichydrocarbons such as benzo[a]pyrene (BP). In non-hepatic humantissues, CYP1A1 is the principal enzyme responsible for themetabolic activation of the proximate BP mutagenic metabolite,(–)-benzo[a]pyrene-trans-7,8-dihydrodiol, to (+)-anti-benzo[a]pyrene-trans-7,8-dihydrodiol-9,10-epoxide,the ultimate BP mutagen. We have genetically engineered bothDNA repair-deficient (xeroderma pigmentosum group A) and DNArepair-proficient human skin fibroblasts to express human CYP1A1under control of the inducible mouse metallothionein-I promoter.CYP1A1 activity was induced by CdSO₄ and monitored by followingthe O-deethylation of ethoxy fluorescein ethyl ester or of 7-ethoxyresorufin.Induced CYP1A1 activities were similar in both cell lines andwere dependent on CdSO₄ concentration and induction time. MaximalCYP1A1 activities were obtained in 4–6 h with 5–7µM CdSO₄. BPD-induced cytotoxicity and hypoxanthine phosphoribosyltransferase mutagenicity were both quantitatively correlatedwith the level of CYP1A1 activity and were greater in DNA repair-deficientcells than in DNA repair-proficient cells. The results suggestthat modestly induced CYP1A1 activity is a risk factor in polycyclicaromatic hydrocarbon-induced carcinogenesis.     

Expression of human cytochrome P450 1A1 in DNA repair deficient and proficient human fibroblasts stably transformed with an inducible expression vector

Cytochromes P450 catalyze the bioactivation of many carcinogens.In particular, cytochrome P450 1A1 (CYP1A1) catalyzes the conversionof polycyclic aromatic hydrocarbons, such as benzo[a]pyrene,into potent mutagenic agents. Human skin fibroblasts, both DNArepair deficient (xeroderma pigmentosum group A: XPA) and DNArepair normal have been co-transformed with a chimeric geneconstruct containing human CYP1A1 coding sequences controlledby the cadmium (Cd) ion inducible mouse metallothionein-I promoterand pRSV-NEO, a dominant selectable marker for G418 resistance.Individual G418 resistant colonies were cloned and analyzedfor Cd inducible CYP1A1 activity. Six clones of DNA repair deficientcells and five clones of DNA repair proficient cells have beenisolated which express Cd inducible CYP1A1. Benzo[a]pyrene-Aww-7,8-diol (BPD) is cytotoxic in Cd induced CYP1A1 expressing cells.The cytotoxkity can be inhibited by 10 µM     

p53-dependent global genomic repair of benzo[a]pyrene-7,8-diol-9,10-epoxide adducts in human cells

The global genomic repair of DNA adducts formed by the human carcinogen (+/-)-anti-benzo[a]pyrene-7,8-diol-9,10-epoxide (BPDE) has been studied by 32P-postlabeling in human fibroblasts in which p53 expression can be regulated. At low BPDE adduct levels (10-50 adducts/10(8) nucleotides), repair was rapid and essentially complete within 24 h in p53+ cells, whereas no repair was detected within 72 h in similarly treated p53- cells. At 10-fold higher BPDE adduct levels, repair under both conditions was rapid up to 8 h, after which a low level of adducts persisted only in p53- cells. These results demonstrate a dependence on p53 for the efficient repair of BPDE adducts at levels that are relevant to human environmental exposure and, thus, have significant implications for human carcinogenesis.     

Chinese medicinal herbs modulate mutagenesis, DNA binding and metabolism of benzo[a]pyrene 7,8-dihydrodiol and benzo[a]pyrene 7,8-dihydrodiol-9,10-epoxide.

Oldenlandia diffusa(OD) and Scutellaria barbata (SB) have been used in traditional Chinese medicine for treating liver, lung and rectal tumors. In this study, the effects of aqueous extracts of these two herbs on benzo[a]pyrene 7,8-dihydrodiol. (BaP 7,8-DHD) and benzo[a]pyrene 7,8-dihydrodiol-9,10-epoxide (BPDE)-induced mutagenesis using Salmonella typhimurium TA100 as the bacterial tester strain and rat liver 9000 x g supernatant (S9) as the metabolic activation system were assessed. We also determined the effects of these two herbs on BaP 7,8-DHD and BPDE binding to calf thymus DNA. Organosoluble metabolites of BaP 7,8-DHD and water-soluble conjugates of BaP 7,8-DHD and BPDE were analyzed by high-performance liquid chromatography (HPLC) and alumina column liquid chromatography. Mutagenesis assays revealed that these two herbs produced a significant concentration-dependent inhibition of histidine-independent (His+) revertants induced by BaP 7,8-DHD and BPDE. OD and SB also inhibited BPDE-induced mutagenesis in a concentration-dependent manner in the absence of S9. SB had a greater inhibitory effect than OD. SB significantly inhibited BaP 7,8-DHD and BPDE binding to DNA while OD significantly enhanced DNA binding of both compounds. OD and SB inhibited the formation of organosoluble metabolites of BaP 7,8-DHD and decreased the formation of water-soluble conjugates of BaP 7,8-DHD and BPDE. However, the fraction of the total radioactivity in the water-soluble conjugates present as sulfate and glutathione was increased by OD and SB. Glucuronide fraction was decreased. The results of this study affirm our previous work suggesting that these two Chinese medicinal herbs possess antimutagenic properties and further suggest that they act as blocking agents through a scavenging mechanism.     

Effects of glutathione transferase activity on benzo[a]pyrene 7,8-dihydrodiol metabolism and mutagenesis studied in a mammalian cell co-cultivation assay

This study deals with the role of glutathione transferase (GST)-mediatedconjugation of (+)-7ß,8-dihydroxy-9,10-oxy-7,8,9,10-tetrahydrobenzo[a]pyrene(BPDE) in two mammalian cell lines, human mammary carcinomacells (MCF-7) and rat hepatoma cells (H4IIE), in relation tothen-capacity to metabolize (–)-trans-7,8-dihydroxy-7,8-dihydro-benzo[a]pyrene[(–)-BP-7,8-diol] to products that induce mutations inco-cultivated V79 cells. Both MCF-7 and H4IIE cells metabolized(–)-BP-7,8-diol to BPDE, but mutations in co-cultivatedV79 cells were only detected with MCF-7 cells. However, depletionof glutathione (GSH) in H4HE cells increased the mutagenidtyof (– )-BP-7,8-diol to a similar level to that found withMCF-7 cells. Measurements of GST activity using GSH and post-microsomalsupernatants from H4IIE, V79 and MCF-7 cells indicated a substantialdifference in conjugation capacity. Although preparations fromall three cell-lines showed GST activity with l-chloro-2,4-dlnitro-benzeneas the substrate, GST activity towards BPDE could only be detectedin supernatants from H4HE cells. This is consistent with thepresence of GST 7-7 an isoenzyme highly efficient hi catalysingBPDE-GSH conjugation. The difference in GSH-conjugation activitytowards BPDE was confirmed using intact H4IIE and MCF-7 cellsin culture. These results indicate that GSH-conjugation playsa pivotal role in mutagenesis induced by polycyclk aromatichydrocarbons (PAH). Accordingly, a deficiency in GSH-conjugationcapacity may be regarded as one important factor in defininga target cell population with an increased risk for tumour initiationfollowing exposure to PAH.     

Benzo[a]pyrene-7,8-diol-9,10-epoxide-DNA adducts and increased p53 protein in mouse skin

p53 protein expression has been shown to increase in responseto DNA damage in cell culture systems. We have Studied p53 expressionand benzo[a]pyrene (B[a]P) -induced DNA-damage in the form ofbenzo[a]pyrene-7,8-diol-9,10-epoxide (BPDE)-DNA adducts as measuredby synchronous fluorescence spectrophotometry (SFS) in B[a]P-treatedC57BL/6 mouse skin. Polyclonal murine antibody CM5, which iscomparable to human CM1, detecting both wild-type and mutatedprotein, was used. BPDE-DNA adducts reached their maximum at24 h after all dosage regimens, but were very well detectablealso at 12 and 48 h after the treatment, while no adducts weremeasurable at 1 week and thereafter. P53 expression was seenin 9/17(53%) skin samples from mouse treated with 500 µgof B[a]P 12–48 h after the treatment, while all 25 (100%)cases of similarly treated mouse skins were negative after 30weeks of the treatment. Only one positive sample of total 11was found among mice treated with repeated 62.5 µg dosesand this was 24 h after the last treatment. After one 62.5 µgdose all mice were negative. This is the first report of anassociation of p53 protein with DNA damage in vivo and givessupport for the putative function of p53 in cellular defensemachinery towards chemical damage.     

Effects of benzo[a]pyrene and ({+/-})-trans-7,8-dihydroxy-7,8-dihydrobenzo[a]pyrene on mitosis in Chinese hamster V79 cells with stable expression of rat cytochrome P4501A1 or 1A2

The effect of bioactivation of benzo[a]pyrene (B[a]P) and (±)-trans-7,8-dihydroxy-7,8-dihydrobenzo[a]pyrene(B[a]P-7,8-diol) on spindle disturbances and toxicity has beeninvestigated in V79 Chinese hamster cells genetically engineeredto express cytochrome P4501A1 (CYP1A1) and cytochrome P4501A2(CYP1A2). B[a]P induces spindle disturbances in native V79 Chinesehamster cells. This effect was enhanced by the expression ofCYP1A1 but not CYP1A2. The increased effect seen in the CYP1A1-expressingcell line could be brought back to the level seen in the nativecell line by     

Transport of DNA-adducting metabolites in mouse serum following benzo [a]pyrene administration

Metabolic activation of benzo[]pyrene (BaP) by cellular enzymesis required for DNA adduct formation. In vivo DNA adducts mightalso arise from BaP metabolites supplied via the systemic circulation,rather than from in situ activation. We determined whether electrophilicmetabolites could be detected in mouse serum 4 h after BaP dosing(i.p.) by trapping metabolites with salmon sperm DNA (ssDNA),followed by ³²P-postlabeling analysis for DNA adducts. In vitrostudies demonstrated that mouse serum sequesters BaP-7,8-diol-9,10-epoxide(BPDE) and protects it from hydrolysis. BPDE was rapidly transferredfrom serum to ssDNA or splenocytes, with adduct levels in ssDNA4- to 7-fold greater than in splenocytes. After BaP administration,mouse serum produced two adduct spots when incubated with ssDNA.The major adduct (spot 3) co-chromatographed with a BPDE adductstandard, while the minor adduct (spot 2) was unrelated to BPDE.A BPDE standard curve in control serum was developed to quantitateBPDE levels in dosed serum. These levels ranged from 13.1 to19.1 nM. Tissue DNA contained three adduct spots: spots 2 and3 appeared identical to the respective adducts arising fromdosed serum. BPDE-DNA adducts in tisues were highest in liver,lung and spleen, with kidney and stomach levels significantlylower. Levels of adduct 2 did not correlate with levels of adduct3, especially in spleen where the adduct 2/adduct 3 ratio wasvery low. In vitro studies in which splenocytes were presentedwith both adducting metabolites suggested that splenocytes preferentiallyform adduct 3. These results indicate that two of the threeBaP electrophilic metabolites responsible for cellular DNA damageare present in mouse serum. The levels of BPDE in serum maybe sufficient to account for a substantial portion of the tissueload of BPDE-DNA adducts.     

Metabolism and DNA adduct formation of benzo[a]pyrene and 7,12-dimethylbenz[a]anthracene in fish cell lines in culture

The metabolic activation of the carcinogens benzo[a]anthracene(BP) and 7,12-dimethylbenz[a]anthracene (DMBA) was examinedin cell lines derived from bluegill fry (BF-2), rainbow trout(RTG-2) and brown bullhead (BB). All three cell lines metabolizedBP (0.5 µg/ml medium) almost completely to water-solublemetabolites within 120 h, but the maximum amount of BP boundto DNA ranged from only 5 pmol/mg DNA in the BF-2 cells to 17in the BB cells and 44 in the RTG-2 cells. The major BP-DNAadduct in the BB and BF-2 cells was that formed by reactionof (+)-anti-BP-7,8-diol-9,10 epoxide [(+)anti-BPDE] with deoxyguanosine.This adduct was also present in the RTG-2 cell DNA, but therewere larger amounts of unidentified polar BP-DNA adducts. Exposureof the cells to [³H]BP-7,8-diol, a metabolic precursor of (+)anti-BPDE,resulted in binding of 1.5, 12 and 35 pmol BP per mg DNA inthe BF-2, BB and RTG-2 cells, respectively. More than 90% ofthe BP-7,8-diol added to the BF-2 cultures was recovered asa glucuronic acid conjugate, but the RTG-2 cells formed moreglutathione conjugates than glucuronide conjugates. The BB cellsformed both types of conjugates at a slower rate for more than75% of the 7,8-diol was recovered unchanged after 24 h. Thethree cell lines differed in the proportion of a 0.1 µg/mldose of DMBA metabolized in 48 h: the values ranged from 47%in the BF-2 cells to 78% in the BB cells and 97% in the RTG-2cells. The amount of DMBA bound to DNA ranged from 4.7 to 8.6pmol/mg DNA in the three cell lines: DMBA-3,4-diol-1,2-epoxide(DMBADE) adducts were present in the BB cell DNA, but no significantamounts of DMBADE-DNA adducts were detected in the RTG-2 orBF-2 cell DNA. These results demonstrate that fish cell culturescan activate BP to an ultimate carcinogenic metabolite, (+)anti-BPDE,but the level of binding of this metabolite to DNA is much lowerthan that which occurs in rodent embryo cell cultures. In BF-2cell cultures formation of BP-7,8-diol-glucuronide effectivelyprevents the activation of this diol to (+)anti-BPDE. A substantialproportion of the BP-7,8-diol is also metabolized to glucuromdeand glutathione conjugates in BB and RTG-2 cells. DMBA alsobinds to DNA at very low levels in these fish cell cultures.Thus effective conjugation of diols and their metabolites byfish cell lines appears to greatly reduce metabolic activationof hydrocarbons through the bay-region diol epoxide pathwaythat predominates in mammalian cell cultures.     

Persistence of benzo[a]pyrene and 7,8-dihydro-7,8-dihydroxybenzo[a]pyrene in Fischer 344 rats: time distribution of total metabolites in blood, urine and feces

A comparison of the rates of elimination of [³H]benzo[a] pyrene(BaP) and 7,8-dihydro-7,8-diol-[³H]benzo[a]pyrene (BPD), aftersubcutaneous injection into Fischer 344 rats, shows they areboth eliminated at about the same rates and with the same patternover at least 7 days post-exposure. The end-rate of combinedurinary and fecal excretion was {small tilde}40 nmol/day. About20% of the injected BaP and {small tilde}3% of the injectedBPD remained at the site of injection for at least 9 days. Theremainder was distributed throughout the animal. If the rateof excretion continued at the observed steady-state rates, theBaP and BPD could persist for up to 40 days for each milligramof injected substance. The concentration of excretion productswere highest during day 1 and day 2 following exposure, decreasedexponentially to a concentration of {small tilde}0.5 µM(mixed metabolites) by day 5 following exposure, and then continuedto be excreted at that rate. Feces contained the highest totalamounts of radioactivity, which were {small tilde}2- to 4-foldhigher than the amounts in urine and {small tilde}15- to 50-foldhigher than in total blood. The conversion of organic ³H to³H₂O during the experimental period indicates.that whole-bodyphenol(quinone) formation was significant for BaP metabolism,but was much less for BPD metabolism. When BaP was injected,both blood and urine contained water-soluble, volatile tritiumcounts (³H₂O). Injection of BPD resulted in volatile ³H₂O inurine but not in blood. The persistence of BaP and BPD metabolitesin skin, blood, urine and feces compartments indicates thereis a substantial reservoir of the chemical(s) that could beused to replenish repaired or discarded DNA adducts.     

Induction of a rat liver benzo[a]pyrene-trans-7,8-dihydrodiol glucuronidating activity by oltipraz and beta-naphthoflavone

We report here that rats possess a hitherto unrecognized xenobiotic- inducible hepatic 7,8-dihydro-7,8-diol-benzo[a]pyrene (BPD) UDP- glucuronosyltransferase (UGT) activity. BPD UGT activity is induced in female F344 rat liver by treatment with the selective Phase 2 conjugation enzyme inducer oltipraz [4-methyl-5-(2-pyrazinyl)-1,2- dithiole-3-thione at 75-450 mg/kg per day for 3 days] and also by a polycyclic aromatic hydrocarbon-type inducer, beta-naphthoflavone (80 mg/kg per day for 3 days). Incubations of oltipraz-treated rat liver microsomes with racemic trans BPD (100 microM) resulted in formation of two fluorescent glucuronides that were resolved by silica thin layer chromatography (Rf 0.5 and 0.6). Incubations with either the (-) or (+) trans BPD isomers resulted in selective formation of the Rf 0.5 [designated -DS, for (-) diol specific] or Rf 0.6 [designated +DS, for (+) diol specific] glucuronide, respectively. The -DS and +DS BPD glucuronides were fluorescent under long wave ultraviolet irradiation, dependent on the presence of UDP-glucuronic acid in the incubation, and were beta-glucuronidase-sensitive. The inducing effect of oltipraz on BPD UGT activity was dose-dependent. The mean BPD UGT activity of the vehicle-treated control group was 0.05 +/- 0.02 nmol/mg per min compared with 0.53 +/- 0.07 nmol/mg per min in the group treated with oltipraz (450 mg/kg per day for 3 days) (P < 0.001). The apparent Km of the induced BPD UGT for BPD was 20 microM, suggesting that the enzyme has the capacity to bind and turnover BPD under physiological conditions. Pretreatment with beta-naphthoflavone, but not phenobarbital, induced BPD UGT activity to approximately the same extent as oltipraz. Neither oltipraz nor beta-naphthoflavone exhibited induction of BPD UGT in livers of homozygous Gunn rats, which lack functional UGT1-encoded isozymes. We conclude that the oltipraz- and polycyclic hydrocarbonresponsive BPD UGT is a member of the UGT1 family. The role of this isoform as a modifier of susceptibility to carcinogenesis elicited by B[a]P remains to be determined.      

High DNA damage by benzo[a]pyrene 7,8-diol-9,10-epoxide in bronchial epithelial cells from patients with lung cancer: comparison with lung parenchyma

In the present study, the level of benzo[a]pyrene 7,8-diol-9,10-epoxide-N(2)-deoxyguanosine (BPDE-N(2)-dG) in normal bronchial epithelial cells from non-cancerous bronchus of 22 lung cancer subjects was evaluated and compared to the lung parenchyma. We found very high formation of BPDE-N(2)-dG adduct in samples corresponding to a pure preparation of bronchial epithelial cells with 4-fold interindividual differences in the DNA adduct levels in the range of 36.5-175.4 BPDE-N(2)-dG adducts/10(8) nucleotides in smokers (mean: 84.7+/-38.4; n = 13) and 3-fold differences in the range of 19.7-62.4 in non-smokers (mean: 37.6+/-22.2; n = 3). DNA isolated from the bronchial tissue consisting of bronchial lining epithelium with adjacent lamina propria showed significantly lower BPDE-N(2)-dG formation (P < 0.001) in the range of 0.4-4.2 BPDE-N(2)-dG adducts/10(8) nucleotides (mean: 1.8+/-0.56; n = 6). This difference is clearly related to the procedure used to prepare the bronchial tissue samples leading to the presence of different types of cells. Eight samples from the normal parenchyma did not show measurable adducts, the other 14 samples showed 50-fold variation (mean: 1.7+/-1.5; range 0.1-5.2 adducts/10(8) nucleotides; n = 14). There were considerably higher adduct levels in pure bronchial epithelial cells than in parenchymal tissue (75.8+/-38.8 vs 0.9+/-1.5 adducts/10(8) nucleotides) (P < 0.0002) BPDE-N(2)-dG adduct concentrate almost exclusively in bronchial epithelial cells. The adduct values obtained in bronchial epithelial cells could be considered as 'critical' for the initiation of human lung cancer. The high formation of BPDE-N(2)-dG adducts in bronchial epithelial cells and investigations showing that the profile of mutations induced by BPDE in these cells is similar to that seen in the p53 gene isolated from human lung tumors implicates benzo[a]pyrene as important carcinogen in tobacco-induced lung cancer in human beings.     

Relationships between benzo(a)pyrene-DNA adduct levels and genotoxic effects in mammalian cells

The effectiveness of benzo(a)pyrene [B(a)P]-DNA binding as an internal dosimeter was evaluated. Data were obtained from concurrent studies, measuring B(a)P induced genotoxic effects and DNA adducts in several short-term bioassay systems: cytotoxicity, gene mutation, and sister chromatid exchange in Chinese hamster V79 cells; cytotoxicity, gene mutation, and chromosome aberrations in mouse lymphoma L5178Y TK+/-; cytotoxicity and enhanced virus transformation in Syrian hamster embryo cells; and cytotoxicity and morphological transformation in C3H10T1/2CL8 mouse embryo fibroblasts. Both total B(a)P-DNA binding and specific B(a)P-DNA adducts were measured. N2-(10 beta-[7 beta,8 alpha,9 alpha-trihydroxy-7,8,9,10-tetrahydrobenzo(a)pyrene]yl)deoxyguanosine [BPDE I-dGuo] was one of the major adducts identified in all bioassay systems. DNA binding and genotoxic responses varied significantly between bioassays. Each genetic end point was induced with a differing efficiency on a per adduct basis. However, the relationships between frequency of genetic effect or morphological transformation and B(a)P-DNA binding or BPDE I-dGuo were linear within a given assay. In order to compare biological end points of diverse frequencies in diverse biological systems, a doubling adduct level, expressed as the number of BPDE I-dGuo adducts per unit of DNA required to double the induced frequency of biological response, was applied to the data.     

CYP1A1 and GSTM1 genotypes affect benzo[a]pyrene DNA adducts in smokers' lung: comparison with aromatic/hydrophobic adduct formation

Benzo[a]pyrene diol epoxide (BPDE)-DNA adducts are involved in the induction of p53 mutations and probably in the causation of human lung cancer associated with cigarette smoking. The ratio between CYP1A1 and GST enzyme activities is a critical determinant of the target dose of carcinogenic BPDE and other DNA-reactive PAH metabolites. In this review, we summarize the published data on modulation of (+)-anti-BPDE-DNA adduct levels in smokers' lungs by CYP1A1*2 genotypes alone or in combination with GSTM1 polymorphism and compare these results with those reported for aromatic/hydrophobic (bulky) DNA adducts. The data published so far show only a trend for a non-significant increase in bulky DNA adduct levels in subjects with GSTM1*0 or the CYP1A1*2-GSTM1*0 genotype combination. In contrast, a clear dependence of (+)-anti-BPDE-DNA adduct levels was found as a function of the CYP1A1 and GSTM1 genotypes: In lung parenchyma, this adduct was more pronounced in persons with the GSTM1*0 genotype, and CYP1A1*2-GSTM1*0 carriers had higher (+)-anti-BPDE-DNA adduct levels than those with CYP1A1*1/*1-GSTM1*0. The homozygous CYP1A1*2/*2 carriers in the GSTM1*0 group had the highest (+)-anti-BPDE-DNA adduct levels. Our analysis leads to the conclusion that the risk-modifying effects of metabolic genotypes and of gene interactions might be more easily identifiable if specific markers of structurally defined adducts were used, such as the (+)-anti-BPDE-DNA adduct. These results are also consistent with the hypothesis that BP (PAH) induce G:C to T:A transversion mutations in the hotspot codons of the p53 tumor suppressor gene and are thus involved in malignant transformation of the lung tissue of smokers.     

Inhibition of DNA synthesis, independent of DNA adduct formation, by benzo[a]pyrene diol epoxide in mammalian cells

Treatment of SV40-infected CV-1 cells with the ultimate carcinogenanti-benzo[a]pyrene diol epoxide (BPDE) at 1 x 10 ^–4 mg/mlor higher reduced the rate of viral DNA synthesis to an extentdependent on the BPDE concentration; similar reductions in cellularDNA synthesis were produced in infected and uninfected cells.Treatment of cells with BPDE, followed by removal of BPDE, atvarious times before infection with SV40 gave the same results.Recovery or partial recovery of DNA synthesis occurred whenthe BPDE concentration was below 6 x 10 ^–4 mg/ml; at higherconcentrations the cells were killed. Simultaneously replicatingviral DNA's from viruses infecting the same cells before andafter BPDE treatment of the cells exhibited the same reducedrate of synthesis. The evidence indicates that covalent adductsin viral DNA are not responsible for its reduced replicationrate; moreover, it is probable that an insignificant numberof adducts is produced in intracellular viral DNA at BPDE concentrationsthat do not kill CV-1 cells. Rather, it appears likely thatBPDE inhibits viral DNA synthesis by attacking cellular DNAor non-DNA targets. Caution is therefore required in relatingthe effects of BPDE and other carcinogens to DNA adduct formation.